Höhn

Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson’s Disease

Retrieved on: 
Thursday, June 22, 2023
Mayo Clinic, University, PD, Serum, The Michael J. Fox Foundation, Immune tolerance, CAPE, Brain, Movement disorder, Doctor of Philosophy, Immunotherapy, Antibody, 2008 Checker O'Reilly Auto Parts 500, Cerebrospinal fluid, Șaeș, MD, Patient, Alpha-synuclein, Observation, CSF, Ageing, Clinical professor, III, Leiden University Medical Center, Synucleinopathy, CHDR, Safety, Conditional sentence, Höhn, Vaccine, Pharmaceutical industry, Part

CAPE CANAVERAL, Fla., June 22, 2023 (GLOBE NEWSWIRE) --  Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines today announced positive results from Part B of its Phase 1 clinical trial of UB-312, an investigational vaccine for Parkinson’s disease (PD), demonstrating UB-312 was well-tolerated and induced anti-alpha-synuclein (aSyn) antibody responses in participants with early PD, meeting the primary objectives of the trial.

Key Points: 
  • Results are consistent with conclusions from Phase 1 Part A and preclinical studies, and support advancement of UB-312 into further clinical development.
  • “These positive Phase 1 results demonstrate several important features necessary for an immunotherapy against Parkinson’s disease and other synucleinopathies to be successful, and represent a further proof-of-principle for Vaxxinity’s platform in chronic disease,” said Mei Mei Hu, CEO of Vaxxinity.
  • “UB-312 was observed to safely break immune tolerance, inducing antibodies against toxic aggregated forms of alpha-synuclein.
  • Together these results support the further development of UB-312 in a Phase 2 clinical trial.

Atomo Coffee Appoints Former Patagonia Provisions and Impossible Execs to the Board of Directors

Retrieved on: 
Tuesday, November 22, 2022
Marketing, Taste, Impossible Foods, Schenck, Food, Coffee, Impossible, Consumer, CMOS, Entrepreneurship, Food industry, Walmart, The Co Founder, CPG, Management, Höhn, Zacarías el Perico

The company launched in 2019 as the world's first beanless coffee, eliminating the environmental costs associated with conventional coffee.

Key Points: 
  • The company launched in 2019 as the world's first beanless coffee, eliminating the environmental costs associated with conventional coffee.
  • Cameron was the Co-Founder and former Head of Patagonia Provisions, the innovative food arm to the sustainable retail giant.
  • Founded in 2019, Atomo is a Seattle-based, food-tech startup that has reverse-engineered the coffee beanproducing an outstanding beanless cold brew coffee that tastes great and does good.
  • Atomo envisions a world where customers never have to compromise their values, taste, or the planet, for a great cup of coffee.

Inhibikase Therapeutics to Present Data from Phase 1/1b study of IkT-148009 at the Movement Disorders Society Congress

Retrieved on: 
Thursday, September 15, 2022
YouTube, Risk, Regulation, Therapy, Neurodegeneration, RAMP, Safety, CEST, Twitter, 201, Brain, Parkinson's disease, International Congress on Tuberculosis, LinkedIn, Company, GI, Imatinib, Form 10-K, Private Securities Litigation Reform Act, Mouse, Patient, Movement disorders, CEO, Höhn, Quality of life, Nasdaq, Congress, Multiple system atrophy, Regulation Fair Disclosure, CNS, Pharmacokinetics, SEC, Neuron, Annual report, Mesylate, Disclosure, Disease, Pharmaceutical industry, Facebook

BOSTON and ATLANTA, Sept. 15, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it will present safety, tolerability, pharmacokinetics and exploratory Parkinson's assessment data from the Company's Phase 1/1b '101' study of IkT-148009 in Parkinson's disease at the International Congress of Parkinson's Disease and Movement Disorders tomorrow, September 16th, 2022. The congress is being held in Madrid, Spain and virtually between September 15-18, 2022.

Key Points: 
  • "We are pleased to present data from the phase 1/1b study of our oral Abelson tyrosine kinase (c-Abl) inhibitor, IkT-148009," said Milton Werner, Ph.D, President and CEO of Inhibikase Therapeutics.
  • EST
    The Phase 1/1b study was a single and multiple ascending dose safety, tolerability and pharmacokinetics trial evaluating once daily administration of IkT-148009 over 7 days.
  • These data highlight that IkT-148009 was well-tolerated, exhibiting linear dose proportionality, high systemic exposure, and persistent penetration into the CNS.
  • Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders.

Peter Hoehn, Accomplished Pharmaceutical Executive, Joins Cohen Veterans Bioscience (CVB) in Newly Created Executive Leadership Role

Retrieved on: 
Monday, August 8, 2022
Nexus, JD, Multimedia, Johnson & Johnson, Precision medicine, CEO, Dementia, Mental health, Science, Marketing strategy, College, Policy, Leadership, Brain, Center for European Governance and Economic Development Research, History of the College of William & Mary, Communication, Research, Foreign policy, BMS, Lists of diseases, Marketing, Biomedical Research, Committee, View, CVB, Therapy, Biotechnology, Doctor of Philosophy, Government, BA, Höhn, Veteran, Solution, Digital health, Economics, Bristol Myers Squibb, Management, Pharmaceutical industry, New York University, MD, Development

NEW YORK, Aug. 8, 2022 /PRNewswire/ -- Peter Hoehn joins Cohen Veterans Bioscience (CVB) as Executive Vice President, Strategic Marketing, Development, and Impact.

Key Points: 
  • NEW YORK, Aug. 8, 2022 /PRNewswire/ -- Peter Hoehn joins Cohen Veterans Bioscience (CVB) as Executive Vice President, Strategic Marketing, Development, and Impact.
  • In this newly created role, Hoehn will lead the External Affairs, Communications, and Development functions for New York-based non-profit CVB which is dedicated to advancing brain health.
  • Peter Hoehn is a proven healthcare business leader with 25+ years' experience in a variety of commercial and strategy roles, predominantly at Johnson & Johnson.
  • Peter started his career as a corporate lawyer and entered the pharmaceutical industry as an attorney for Bristol Myers Squibb.

Characteristics of hospitalized COVID-19 patients with Parkinson's disease

Retrieved on: 
Tuesday, September 14, 2021
MDS, Höhn, Hospital, Education, Incidence, Parkinson's disease, PD, Delirium, Health, Encephalopathy, Patient, Government budget balance, Brain damage, Literature, Risk, Mortality, Disease, Physician, MD, Death, Record, COVID-19, Hypertension, Lists of diseases, Movement disorders, Dementia, Research, Pharmaceutical industry

Understanding which patients with PD are most likely to need hospitalization due to COVID-19 infection and the associated outcomes can help clinicians advise those in their care.

Key Points: 
  • Understanding which patients with PD are most likely to need hospitalization due to COVID-19 infection and the associated outcomes can help clinicians advise those in their care.
  • studied the patients with PD who were hospitalized with COVID-19 infections.
  • The team examined the clinical characteristics and the mortality rates of the patients of interest.
  • They found that the patients were majority mid- to advanced PD, on pharmacological therapies for their PD, and older.